http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
-
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
-
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors
-
Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
-
Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
-
KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
-
Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
-
Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
-
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer
-
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer
-
Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The
-
Merck Receives 2015 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency
-
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
-
Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28
-
Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia
-
Merck Announces New $10 Billion Share Repurchase Program
-
Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early
-
Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
-
New Data Investigating Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
-
New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presentin
-
Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection
-
KEYTRUDA® (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma
-
Merck to Present at the Barclays Global Healthcare Conference
-
Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in C
-
Cubist Pharma (CBST) Declines: Traders Discuss Patent Dispute vs Hospira (HSP)
-
Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
-
Market Wrap: Valeant Lifts Allergan Bid; Twitter's Ho-Hum Q3 Report; Tesla Slumps on Sales Speculation
-
Trading Radar for 10/27: Twitter (TWTR), Buffalo Wild Winds (BWLD), Crocs (CROX), Huntsman (HUN) Report
-
Notable Analyst Rating Changes 10/2: (TWTR) (ADSK) (AKS) Upgraded; (JPM) (ENPH) (ETN) Downgraded
-
Market Wrap: Home Prices Gain at Slower Pace; Twitter Soars in Q2; Ford Opts for Apple
-
Trading Radar for 07/29: Pfizer (PFE), Marriott (MAR), UPS (UPS), Anadarko (APC), Ballard Power (BLDP) Report
-
Market Wrap: Confidence Dips in April; Nokia's New Game Plan; Twitter De-Feathered on Results
-
Trading Radar for 04/29: eBay (EBAY), Twitter (TWTR), Nokia (NOK), Express Scripts (ESRX), Seagate (STX) Report
-
Market Wrap: CVS Quits Tobacco Cold Turkey; 3-D Printers Hit on Warning
-
Trading Radar for 02/05: Disney (DIS), Time Warner (TWX), Humana (HUM), Green Mountain (GMCR), Pandora (P) Report
-
Pre-Open Stock Movers 1/13: (ALNY) (BEAM) (CHC) Higher; (ICPT) (SODA) (LULU) Lower (more...)
-
Top 10 News for 09/30 - 10/4: U.S. Govt Shuts Down; Twitter to Go Public; Tesla Fire Cools Run
-
Market Wrap: Manufacturing Ramps in Sept.; Govt. Shutdown: Day One; Merck Makes Adjustments
-
Idenix (IDIX) Surges As Rumor Mill Enters Overdrive

